Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (OP:RVVTF)

0.0096 UNCHANGED
Streaming Delayed Price Updated: 3:02 PM EDT, Mar 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0096
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0096
Today's Range 0.0096 - 0.0096
52wk Range 0.0050 - 0.0242
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Revive Therapeutics Announces Results of Annual Shareholder Meeting
From Revive Therapeutics Ltd.
Via GlobeNewswire
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading... 
Via Newsfile
Exposures Product Safety

Performance

YTD
+84.6%
+84.6%
1 Month
+26.3%
+26.3%
3 Month
+57.4%
+57.4%
6 Month
+35.2%
+35.2%
1 Year
-57.3%
-57.3%

More News

Read More
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
From Revive Therapeutics Ltd.
Via GlobeNewswire
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Via Benzinga
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Corporate Update
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
From Revive Therapeutics Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
From Revive Therapeutics Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Revive Therapeutics Ltd publicly traded?
Yes, Revive Therapeutics Ltd is publicly traded.
What exchange does Revive Therapeutics Ltd trade on?
Revive Therapeutics Ltd trades on the OTC Traded
What is the ticker symbol for Revive Therapeutics Ltd?
The ticker symbol for Revive Therapeutics Ltd is RVVTF on the OTC Traded
What is the current price of Revive Therapeutics Ltd?
The current price of Revive Therapeutics Ltd is 0.0096
When was Revive Therapeutics Ltd last traded?
The last trade of Revive Therapeutics Ltd was at 03/27/25 03:02 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.